<sup>18</sup>F-FDG PET/CT在阿帕替尼治疗肺多发转移性碘难治性分化型甲状腺癌评估中的价值

张迎强; 张　鑫; 王　宸

doi:10.19401/j.cnki.1007-3639.2018.07.005

您当前的位置：

首页 >

文章列表页 >

¹⁸F-FDG PET/CT在阿帕替尼治疗肺多发转移性碘难治性分化型甲状腺癌评估中的价值

专家述评与论著 | 更新时间：2026-01-27

- ¹⁸F-FDG PET/CT在阿帕替尼治疗肺多发转移性碘难治性分化型甲状腺癌评估中的价值
- The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy
- 中国癌症杂志 2018年28卷第7期页码：505-510
- 作者机构：
  
  1. １. 中国医学科学院北京协和医学院北京协和医院核医学科,北京,100730
  2. ２. 核医学分子靶向诊疗北京市重点实验室,北京,100730
- 作者简介：
- 基金信息：
  
  国家自然科学基金（81571717，81771875）;中国医学科学院医学与健康科技创新工程（2016-I2M-2-006）。
- DOI：10.19401/j.cnki.1007-3639.2018.07.005
  中图分类号： R736.1
- 网络出版：2018-08-10，
  
  纸质出版：2018-08-10
- 稿件说明：
移动端阅览
张迎强,张　鑫,王　宸,等.

张迎强, 张　鑫, 王　宸. The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy[J]. China Oncology, 2018, 28(7): 505-510.
张迎强,张　鑫,王　宸,等. DOI： 10.19401/j.cnki.1007-3639.2018.07.005.

张迎强, 张　鑫, 王　宸. The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy[J]. China Oncology, 2018, 28(7): 505-510. DOI： 10.19401/j.cnki.1007-3639.2018.07.005.

摘要

背景与目的：碘难治性分化型甲状腺癌(radioactive iodine-refractory differentiated thyroid cancer，RAIR-DTC)是近年来研究的热点。因肿瘤细胞的异质性，不同病灶的生长速度及治疗疗效不尽相同。该研究探讨

F-FDG PET/CT在RAIR-DTC多发肺转移患者经阿帕替尼治疗效果评估中的价值。方法：纳入于中国医学科学院北京协和医学院北京协和医院经阿帕替尼治疗的RAIRDTC患者。入组患者于基线、治疗后4周及8周行CT及

F-FDG PET/CT检查。结果：共7例患者，49个肺转移灶，SUV

max

在基线时为0.8~23.2。基线时病灶的SUV

max

水平与治疗后4周及8周的SUV

max

变化（SUV

max-4w

/SUV

max-baseline

，SUV

max-8w

SUVmax-baseline

）显著相关(P0.000 1，P0.000 1)。4周及8周的病灶直径变化率(CT4w/b，CT8w/b)与基线SUV

max

无明显线性相关（P=0.666 4，P=0.478 7）。而4周的SUV

max

变化（SUV

max-4w

/SUV

max-baseline

）与CT4w/b及CT8w/b显著相关（P=0.033 3，P=0.004 8）。对于基线水平SUV

max

大于5的病灶，SUV

max-baseline

与CT4w/b、CT8w/b均具有线性关系（P=0.008 2，P=0.016 9）。结论：

F-FDG PET/CT在RAIR-DTC多发肺转移患者靶向药物治疗中具有广阔的应用前景，可以识别肿瘤一致性，辅助选取靶病灶，并通过病灶的SUVmax预测患者对靶向药物治疗的疗效。

Abstract

Background and purpose: Radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) is a hot topic in recent years. The growth rates of different lesions and their responses to treatment vary a lot due to the heterogeneity of tumor cells. This study aimed to explore the value of

F-FDG PET/CT in RAIR-DTC after the therapy of apatinib. Methods: RAIR-DTC patients undergoing apatinib therapy in Peking Union Medical College Hospital were enrolled.

F-FDG PET/CT was performed at baseline

4 weeks and 8 weeks after apatinib therapy. Results: A total of 7 patients including 49 lung metastases were analyzed after apatinib therapy

with SUV

max

varying from 0.8 to 23.2. The results showed that the SUV

max

level of lesions at baseline was significantly associated with the changes in SUV

max

at 4 and 8 weeks after the treatment (SUV

max-4w

/SUV

max-baseline

SUVmax-8w/SUV

max-baseline

) (P0.000 1

P0.000 1). The rate of lesion diameter change (CT4w/b

CT8w/b) was not correlated with baseline SUV

max

at 4 weeks and 8 weeks (P=0.666 4

P=0.478 7). The 4-week change in SUVmax (SUV

max-4w

/SUV

max-baseline

) was significantly associated with CT4w/b and CT8w/b (P=0.033 3

P=0.004 8). For lesions with baseline SUV

max

greater than 5

SUV

max-baseline

had a linear relationship with CT4w/b and CT8w/b (P=0.008 2

P=0.016 9). Conclusion:

F-FDG PET/CT has great value in evaluating the heterogeneity

selecting target lesions and predicting the response in patients with RAIR-DTC after apatinib therapy.

关键词

Keywords

references

浏览量

2127

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

弥漫性大B细胞淋巴瘤基因变异特征与¹⁸F-FDG PET/CT SUV_max的关系解析及其临床意义

颈部超声联合血清甲状腺球蛋白评估阿帕替尼治疗进展性碘难治性分化型甲状腺癌的短期疗效

阿帕替尼治疗晚期胃癌的疗效预测和预后分析

甲磺酸阿帕替尼治疗进展性碘难治性甲状腺癌的短期疗效及安全性初步报告

¹⁸F-FDG PET/CT在评价索拉非尼治疗¹³¹I难治性分化型甲状腺癌疗效中的应用

18F-FDG PET/CT在阿帕替尼治疗肺多发转移性碘难治性分化型甲状腺癌评估中的价值

The value of18F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy

DOI：10.19401/j.cnki.1007-3639.2018.07.005

摘要

Abstract

关键词

Keywords

references

¹⁸F-FDG PET/CT在阿帕替尼治疗肺多发转移性碘难治性分化型甲状腺癌评估中的价值

The value of¹⁸F-FDG PET/CT in the evaluation of multiple lung metastatic radioactive iodinerefractory differentiated thyroid cancer after apatinib therapy